Serina Therapeutics Receives $5M To Advance Parkinson’s Drug Into Human Trials

Serina Therapeutics Inc. accomplished the second phase of its strategic funding initiative, totalling $10 million, by finalising its agreement with JuvVentures (UK) Limited. Thus, the investment enables Serina to fund the development of SER-252 (POZ-apomorphine) through Phase 1 clinical trials with advanced Parkinson's patients and provides financial capacity for the second half of 2025. The $10 million funding from December 2, 2024, underwent its second and final stage, completely closing the project.  

Steve Ledger, CEO of Serina Therapeutics, said in a statement, “This financing strengthens our cash position as we advance SER-252 into the clinic. With a differentiated approach to continuous dopaminergic stimulation and an innovative drug delivery system, we believe SER-252 has the potential to provide meaningful benefits for patients with Advanced Parkinson’s disease. We remain focused on initiating our Phase 1 trial in the second half of this year.”

The obtained funds strengthened Serina's ability to conduct initial human studies for SER-252. Serina distributed 500,000 common stock shares for $10 per share during the closing, which provided owners with a 113% above market value based on January 31, 2025 closing rates. The company provided JuvVentures with the right to buy up to 755,728 common stock shares, payable at a fixed price of $18.00 per share through its issued warrants.